Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lets hope this isn't round two of them pumping it up. I'd rather have news.
The hack that created unnecessary panic has kept us down here. We should be hovering around .01 not .008
I hope everybody has seen the stickie that was posted!
Agreed. Patience seems to always be key down here with company's that are transparent and have potential. Good to get in early and reap rewards later.
Sorry cant reply to PM. Based on my time in Europe, I see that they don't view their pharma products the way us Americans do. I think the reworking of the formula also will have to do with FDA regulations more so than potency.
I got in at .05. I agree with you but would love to see a piece of news to put this on other investors radar.
Moving on some low volume.
I think somebody on the board received an email last week from Dr. S regarding the tweaking of the formula. I would assume North American trials would be more stringent??
I am not sure where I read this, but I believe they are altering the formula slightly for the North American trials.
Yea but the cheeky bugger shouldn't reap the rewards with the rest of us. I am glad i was out of the house during that time period.
Id be interesting to find out who was buying when the bashing tweets were sent out.
Not a basher but new here. Anybody clarify this??
http://www.otcmarkets.com/stock/WNWG/quote
OTC Markets has discontinued the display of quotes on www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware) and because adequate current information has not been made available by the issuer of the securities. It has been labeled Caveat Emptor for one of the following reasons:
Questionable Promotion — The security is being promoted to the public, but adequate current information about the issuer has not been made available to the public.
Spam — The security is the subject of spam promotion having the effect of encouraging trading of the issuer's securities.
Investigation of Fraud — There is a known investigation of fraudulent activity involving the company, its securities or insiders.
Suspension/Halt — A Regulatory Authority has halted or suspended trading for public interest concerns (i.e. not a news or earning halt).
Disruptive Corporate Actions — The security or issuer is the subject of corporate actions, such as reverse mergers or serial stocks splits and name changes, without adequate current information being publicly available.
Unsolicited Quotes — The security has only been quoted on an unsolicited basis since it entered the public markets and the issuer has not made adequate current information available to the public.
Other Public Interest Concern — There is, in OTC Markets' view, a public interest concern.
Consequently, OTC Markets has removed the quotes from this website until adequate current information is made available by the issuer pursuant to OTC Markets Group's Guidelines for Providing Adequate Current Information (PDF) and until OTC Markets believes there is no longer a public interest concern. Investors are encouraged to use care and due diligence in their investment decisions. Please read our Investor Protection page for more information.
I would think Memorial Day
Yes sir. Looking for a nice bit of news now.
Very quiet over here. Another week without news. We are due no?
Ive got the ask again at .55
Yea I made that mistake with LEXG, bought the pump at $2 and panicked at the first drop thinking here come the shorts and it shot to I believe $12!
Fingers crossed on successful North American trials. European trials are a good step but still a step none the less.
That would be delightful but it's also quite possible it gets swallowed up before then by a giant. I'll take either of those!
I'll take a green day for once!
I also have an ask at 1.01
Yea agreed. Will add to my position when I can...
BUENA PARK, CA, May 10, 2011 (MARKETWIRE via COMTEX News Network) -- SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced financial results for the Company's fiscal first quarter 2011, ended March 31, 2011.
Revenue in the fiscal first quarter of 2011 was $145,402 compared to revenue of $200,324 reported in the year ago period. The net loss for the first quarter was $161,019, as compared to a net loss of $554,708 reported in the same period last year. This significant improvement is evidence of SOHM's focus on cost containment, and the Company reiterates its projection that fiscal 2011 will be the first year of profitability with revenues expected to be in excess of $1,250,000.
Shailesh Shah, President and CEO of SOHM, Inc. stated, "Although first quarter sales were down 27%, our net loss improved 70% and these numbers were in line with our internal projections. We continue to implement policies and procedures that we expect will cut costs and allow us to attain profitability by the fourth quarter."
"I'm happy to confirm that we are moving forward adequately with the previously announced acquisition and expect to make further announcements within the next 90 days. This is an exciting time for the SOHM, as our progress speaks to the viability of our business model and we feel that we are in an enviable competitive position in the rapidly growing generic pharmaceutical marketplace," continued Mr. Shah.
"In addition to meeting our internal goal of profitability this year, we expect acceleration of revenue growth through organic growth and acquisitions," concluded Mr. Shah.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. The Company's global headquarters is located in California, USA, with manufacturing facilities in India. SOHM, Inc. exports generic pharmaceuticals globally, with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Whats your overall thought on this? Was the purchase of the derma company after March 31st?
What are your long-term views on this?
Staying strong on little volume too.
Yea completely agree with you there. I've got mine sitting and waiting. Hopefully we will see some volume once all the details come out regarding the acquisition.
I've only got a small position here. Seems like a business model that could do well in a region that has the potential to boom. Curious as to how earnings will be.
Are you referring to the acquisition of the dermatology company?
Great stock to use yours posts on!
Ah I see. Thanks for that.
Excuse my ignorance, still new at this, but how are you able to track them selling off shares?
Beautiful chart. Broke through resistance and hopefully can keep support now. Lots of room to run. Love to see all this green.
http://stockcharts.com/h-sc/ui?s=FRDM&p=D&yr=1&mn=0&dy=0&id=p80683974644
Dont understand why it dives so hard on news. Anybody?
Testing the resistance at .08 Would be good to get in the financials and see some more volume towards the close.
NEWS
SOHM, Inc. Announces Surge in Demand for Its Generic Pharmaceuticals Within India
05/03/2011 09:02:22 ET
India's Generic Drug Market Projected to Grow at a CAGR of Around 16.3% During FY 2011-FY 2013
BUENA PARK, CA, May 03, 2011 (MARKETWIRE via COMTEX News Network) -- SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that demand for its branded pharmaceutical products has surged within India. In line with the Company's growth target of 200% in 2011 new product offerings and expanding market share are expected to drive sales.
India is considered one of the fastest growing pharmaceutical markets in the world. The introduction of new products coming off patent protection has put the industry growth on a new path. Research report "Booming Generics Drug Market in India," has the generic drug market in India projected to grow at a CAGR of around 16.3% during FY 2011-FY 2013.
"Blockbuster drugs continue to lose their patent protection which creates a constant new product pipeline for generic drug manufacturers like SOHM," stated Shailesh Shah, President and CEO of SOHM, Inc. "Asthma treatment, Advair and anti-cholesterol pill, Lipitor have both recently lost patent protection which has been a significant new area of growth for our Company. Demand in emerging markets like India for affordable drugs continues to ramp up and there is no denying the scale of the opportunity these markets present. Research analysts continue to point at population growth in emerging markets, but what is important is rising demand driven by the increasing middle classes and their increasing appetite for affordable high quality drugs."
About SOHM, Inc. SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
SOURCE: SOHM, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=942AAEE28141BA3A
Copyright 2011 Marketwire, Inc., All rights reserved.
Not that this is substantial but a start regarding their recent acquisition.
Dear investor,
Thank you for your email and noted the contents. Proper due diligence as well as negotiation is going on in right directions and it will be disclosed to our investors in due course of time.
Due to confidentiality reasons it is too early to release the name of the dermatology company at this stage.
Thank you for your email.
Investor Relation Team
SOHM, Inc.
www.sohm.com <http://www.sohm.com>
Ph: +1 (714) 522-6700
Email: ir@sohm.com
Good find. Hopefully we won't slip another .30 cents. I am long on this one. Very curious as to how it will play out with their patents.
Been finishing strong for the past few closes. Could break through resistance today at .0660 then it's clear skies past .07
Strong close! Looking to Monday.
http://www.peopledeals.com/ is already up and running. has my location entered automatically and show's the nearest deals around. Makes sense. However too much of a coincidence that the same day PLPE launches People Deals, Facebook launches Facebook Deals. The only difference is that PLPE have patents pending which may or may not be an advantage.